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Bn ,dients with a myocardial infarction, coronary 
rkmnbQsis is often cawe of the occiusion Qf Ehe cm~- 
nar, artery and the onset of myocardial infarction (1). 
Resolution of the coronary thrmbus is the aim of ireatment 
with thrambolytic agents (2). Since the introduction of 
tkrombolytic Fhempy for suspected acute myocardial infarc- 
tion, the evidence for the benefit d his treatment has been 
QVC3-Whd~li~~. &pd.BiQll raFe Of the ~~~~C~~~~l~t~~ ank3J’ 
W’kS fKM-il409-6 tQ 85% (3-7). 
After successful thrQmbolytic therapy, recwrent isch- 
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‘11‘ 1. Diameter Stenosis Grading by the European Coqerative 
Study Group 
Grade of 
stenosis 
3 91% to 99% iiimetet stenosis, complete filling within 3 cycles 
4 91% to 99% diameter stenosis, no complete filling within 3 cycles 
5 Total occlusim with or without cdlateral filtim 
years old with chest pain For >30 min, who 
were treated with streptokinase or 
30 to 60 min, and ANAC was 
so a reason for excfusion. After g&it-q in- 
tients were randomized by a central 
ree treatment arms. In 
once daily) Qr placebo, 
nts treated with ~~~rnadin, 
uiiation was estab- 
@?R 2.8 to 4.Q. AU patients were FoHowed up daily 
stay and visited the outpatient clinic 
p period of 3 months. A conservative 
ww unended. R~vascufarization procedures during 
the follow-up eriod OF 3 months were performed only if 
clinically indicated (angina reFractabry to medicati 
never based on ~~iogr~~~~c Features. 
After 3 months, a second an 
formed to determine r occlusion. 
tams were an i~d~~~t~~~ for the
formed earlier. In case of ~~~~~~~y a 
rut, 
intention to treat principle, 
Power calculations for the therapeutic groups were made. 
These data are reported in detail in B recen 
that provides the clinical data from the 
Because the expected reoccllusisn rate aft 
unknown, adequate calculation of statistical power For the 
detection of differences between the two categories of ste- 
nosis everity was not possible. 
On behalf of the Scientific Council of the Interuniversity 
Cardiology Institute of the Netherlands, an external r;Rnical 
epidemiologist ~~Qrrned interim analysis on the basis of the 
intention to treat principle after 100 and 2 
protocJ changes were indicated. 
Three hundred patients were included in the APRICOT 
study. Retrospectively, the angiography committee x- 
ieats because the infarct-r 
(1 receiving ~o~mad~~, 5 
11 (5%) underwent coronary bypass 
coumadin, 8 placebo). On clinical indi- 
cations and after ecur~~t myocardial infarction, 5.5 patients 
underwent repeat a~~~~g~ 
protocol. In 31 (56%) 
found. 
c Characteris- 
ts with iaargio- 
graphic follow-up are listed in Table 2. There were no 
significant diITerences in age, time delay in start of throm- 
bolysis and timing of angiography among the diEerent treat- 
are shown in Table 3 
the first and second an 
the placebo group (p = 
Reocclusion rate increased with culprit lesion ~tmxh se- 
14% VEENETAL, 
ANOIOOaAPHICFEATORESRELATEDTQREOCCLUSlON 
JACC Vol. 22, No. 7 
3. &s&e Demographic, Clinical and Augiographic Characteristics of Patients 
ut a Second Coronary Angiogram 
With Without 
Second Angjopm Second Angiogram 
(n = 248) [II = 36) 
Age (YrI 56 + 9 HI ‘5 5 
%men 83 bs, 
Previous inkction (%) 5 17 
Tii to thrombolysis (h) 2.0 2 1.0 2.2 k 12 
mt (%I 
88 82 
Alarepb 12 8 
hwwwus rrtenalot (%> 42 50 
PO& CKM9 (LMh) 121 T 101 I2 J- 93 
Timtt from thromblysie to idial 24” 14 28 h I2 
a) 
In wssel(%6) 
42 34, 
Lax I& 14 
RCA 42 43 
Culprit Man !mlosis werlty (96) 
9 3 
62 33 
29 M 
c 
li6 58 
Complex 44 42 
Sitie-vessel dwe 6%) 53 58 
0.33 to 1.3% for aSppirin 0.44 to 1.73 for caumadin. 
0 1.0 2.0 
trwbnsint tnatmubt 
batter wrsa 
4. Reocclusioa Rates According to Stenosis Severity 
and Mxphology at Initial Angiography 
StWkXfS bocclusion 
Variable No. No. % 
Morphology 
Complex 
Smooth 
23 4 17 
1153 37 23 
72 30 42* 
108 24 23 
140 47 34t 
*p < 0.01, NJ% versus -SOS. tp < 0.05, smooth versus complex. 
at the end of the 
m which reocclu- 
sion was shown to be relate e clinical outcome 
(e.g., recurrent ischernia and 
ieft ventricular function). The study of Ohman et al, (16) also 
is an adverse vent. 
Studies reporting reoe- 
treatment regimen (8,20,28,2 
(15,16)orwiththepredictionofreocclusiorm(13,14,22,23,30- 
32). The reocclusion rate 7 to 14) days after successful 
ies (~3,~4~~2~23~. A 
ctor for reoccIusion 
part of the prckxxl. One of these 
residual ritencsis severity as a 
emia and, ~~f~~t~~ate~y* 
stenosis severity did not 
large scale study reported here, in which reocclusion was a 
primary end point and core 
indicat 
or for subsequent reocclusion 
han two thirds of the patients 
eocctusion Rates According to C~slpr~t Lesion Stenosis Severity, Lesion ~0~~~~~~~ and ~~t~t~~~~~~ti~ ~~ t~~~t 
- 
Lesion Stenosis Severity Lesion Morphslo~y 
.m?.-Vl--V 
>w% -GM% SilWOlh COIt@!ZX 
P -__ll P 
Treatment NO. % NO. % Value NO. % NO. % VUlllC 
__I_i)_ll Aspirin 12127 44 11166 < 0.01 17149 35 6/44 I4 < 0.02 
Coumadin 10/25 40 14156 25 NS I.5153 28 9118 32 NS 
Placebo 8120 40 16153 30 NS 15138 40 9130 25 kds 
176Q VEBN ET AL, 
AN~IOGRAPHXCFEArmaESRELATfiDTOREOeCLUSfON 
CWle 95% AdjUSkd 95% P 
OR Cl OR Cl Value 
r&tics of rhe culgrit lesion just 
fore planned elective ~~~~~~y 
mbolysis were described by 
They could not identify 
recurrent ischemia or 
practice, where ~uant~ficatio~~ is timeconsuming, ~rn~r~ct~~ 
cd and cumbersome. and 
s in 
fmc selection and n can give rise to 
aracterization f a stenosis (39). 
Recent studies demonstrate that 
coronary angioplasty foroptimal patient care is not indicated 
without ischemic signs after thrombolysis (15,21). In our 
study, angioplasty was not intended, and therefore the 
ration between the cul 
lysis and reacelusion 
y planed invasiv previously described 
simple angiographic features ofthe culprit lesion are easy to 
obtain doing routine angiography without automated quan- 
titative analysis and strongly predict reocclusion after SW 
cessful thrombolysis. 
Because r occlusion significantly interferes with left ven- 
tricular function (16), it should be prevented by all means. In 
a recent publication (24) from the APRICOT trial it was 
We arc indebted lo Jan G. P. Tijssen, PhD, clinical epidemiologist, for his 
scientific support. 
A, Spores J, Not&e I%, et al, Prevalence of total coronary 
uring the early hours of transmural myasardial infarction. 
2. Rentrop KP, Blanke Karsch KR. Acute myocardial infarction: intra- 
coronary application df nhroglycerin and strcptokinase. Clin Cardiol 
1979;2:354-63. 
3. Spann JF, Sherry S, Carabello BA, et al. Coronary thrombolysis by 
intravenous stre~tok~~ase in acute myowrdial infarction: acute and 
folailow-up studies. Am J Cardiol 1984;53:65%68. 
4. Verstraete M, Bernard R, Dory M, et al, Randomised trial of intravenaus 
recombinant tissue-type plasminogen activator versus intravenous strep- 
tokinase in acute myocardial infarction. Lance1 1985;1:842-7. 
5. Chesebro JII, Knatterud G, Roberts W, et al. Thrombolysis in myncardial 
infarction (TIMI) trial, phase I: a comparison between intravenous tissue 
plasminogen activator and intravenous streptokinase. Circulation 1987; 
76: 142-54. 
6. Chesebro JH, Knatterud G, Braunwald E. Thrombolytic therapy. N Engl 
J bled 1988;319: 1544-T. 
7. Mueller HS, Rao AK, Forman SA, and the TIMI Investigators. Throm- 
bolysis in myocardial infarction (TIMI!: comparative studies of coronary 
repcrfusic 1 and systemic fibrinogenolysis with two forms of recombinant 
tissue-type plasminogen activator. J Am Coil Cardiol 1987;10:479-90. 
8. Verstraete M, Arnold AER, Brewer RW, et al. Acute coronary throm- 
bolysis with recombinant human tissue-type plasmirogcn activator: initial 
patency and influence of maintained infusion on reocclusion rate. Am J 
Cardiol 1987;60:231-7. 
9. Bonnier NJRM, Visser RF, Klomps NC, IIoffmann NJML, and the Dutch 
Invasive Repeffusion Study Group. Comparison of intravenous aeisoy- 
lated plasminogen streptokinase activator complex and intracoronary 
streptokinase in acute myocardial infarction. Am J Cardiol 1988;62:25-30. 
10. Verstraeke M. Thrombolytic Treatment in acute myocardial infarction. 
Circulation 1990;82 SoppI II:II-96-109. 
17. 
18. 
19 
20 
21 
22. 
23. 
24. 
25. 
26. 
27. 
. Factors i~fl~eac~~~ reocclusion after 
rsncclusion rum rcaluctioa in late coraanery artery stenosis following 
tbrombolytic therapy in patients with acslte ayocardhl ~nf~ctio~~ a 
r~~~~~~?~l~~~~d study of ~~~i~~t~~~a~~ce infusion of recombinant human tissue- 
type plasmiuogcn activator. Ci 
Ellis SC. Topol EJ. Gearye 
warning: analysis of risk faclor 
successful ihrombolysis with intravenous tissue plasminogen activator. 
Circulation 65. 
White CW. chemic events after successful ~~~~m~~~y§~s in 
my0c on. Circulation t989~~~t4$2-5, 
‘op KP, Feit F, Sherman W. Thornton JC. Serial angiographic 
sment of coronary artery obstruction and tsral Row in acute 
myocardial infarction: report from the second I Sinai-Mew York 
University reperfusion trial. Circutation l989;gtk 
The ‘FIlMI Study Croup. Comparison of invasive and conservative strat- 
egies after treatment with intravenous tissue ~las~~flo~cn activator in 
acute myocardial infarction: results of the Thrombolysis in 
infarction (TlMI) phase 81 trial. N Engl J 
S, h-own BG, Kennedy JW, et al. lJsefulaess af reca~~i~t~~m 
to lumenal diameter of 0.6 mm or more with intracoronary ~t~c~~o~i~ase 
during acute myocardial infarction in predicting “normal” perfusion 
status, combined ai~ial patsncy and survival at one year. Am 3 Cardiol 
1987;59:589-22. 
Narrison DC. Hcrgusan 
rcperfusion with streptok 
sions. Circulation l9~;6~~~1-9. 
Meijer A, Verheugt FWA, 
Eenige MJ. Aspirin versus 
recurrent ischemia after successful thrombolysis: a prospective placebo- 
controlled angiographic study. Circulation 1993;87.1524-30. 
Verstracte M, Brewer RW, Dunning AJ, et al. Double blind randomized 
trial of intravenous tissue-type plasminogen activator versus placebo in 
acute myocardial infarction. Laecet 1984;2:%5-9. 
Ambrose JA, Winters SE, Stern A, et al. An~io~~hic morphology and 
the pathogenesis of unstable angina pectoris. J Ant Colt Cardiol I985;5: 
609-16. 
Ambrose JA. Winters SL, Arora 
morphology in myasardial infarction: a I’imk between the pathogeeesis of 
unstable angina and nyocardial infarction. J Am Coll Cardiol 1985:6: 
1233-B. 
28. Califf RM. Toool EJ. Stack RS. et al. Evaluation of combined throm 
lytic ther&y and timing of cardiac cathetc~zatio~ in acute my~~$iaI 
infarction: results of TAMI-phase 5 raadom~~cd trial. Cjrc~I~tio~ 1991; 
83: 1543-56. 
Anderson JL. Rcpcrfusion, patency aad rcocclusion with anictreplase 
(APSAC) in acute myocardial infarction. Am J Crrdial 1989; 
djrines CL, Topol EJ, Rates RR, Jurri J%, Walton IA, Q 
Infarct vessel status after intravenous tissue plasminogen activator and 
acute coronary angioplasty: prediction of clinical outcome. Am Heart J 
1988;115:1-7. 
Plakagawa S, Hanada Y, Koiwaya Y, Tanaka K. Angkgraplk features of’ 
the infarct-related artery after intracoronry urokinase followed by pro- 
anticoagulation, circulatioKl 1988;78:1335-44. 
32. DC, Gardincr GA, Complex and simple coronary artery stews&: 
a new way to intemt coronary angims based on morphologic 
ions, Radiology 1%7;164:675-80. 
33, Sorensen SG, Menlove RI.,, Moreno F, Anderson JL. 
’ myocardii infarction (TM) perfusion grade 2 
ent or a mostly occluded artery? Enzymatic and 
evidence from the TEAM;? k&y, 1 Am Coil Cdiol 
34, Davies SW, Mar&ant B, Lyons JP, et al, Coronary lesion morphology in 
acute myocankil nfarction: demonstration of early remodeling after 
rtreptoBnase trMment. J Am Call brdiol la90;16:1099-B. 
35. O’Brien JR. Fbhw~induced plhtelet tion, Lancet 1 ;335:7114. 
and pmsl visual im?r* 
10s~ for cLnical decisions. 
N, 
sions resulting from variations in citteframe s lection. Catbet C
Diagn f988;14:221-8. 
39. Gurley JC, Nissem SE, Booth DC, Dehkria AN. In&~ence of 
and patient-depedent variables on th  uitability of automated qurmtita- 
tivc Goron raphy for routine clinical use. J Am CoBI Cardiol 
1992;19: 231-43. 
